High-fructose and high-fat feeding correspondingly lead to the development of lysoPC-associated apoptotic cardiomyopathy and adrenergic signaling-related cardiac hypertrophy

International Journal of Cardiology

Volumn 215, Issue , 2016, Pages 65-76

  Huang, Jiung Pang ^a   Cheng, Mei Ling ^a,b   Wang, Chao Hung ^b   Shiao, Ming Shi ^a   Chen, Jan Kan ^a   Hung, Li Man ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Apoptotic cardiomyopathy; Fibrotic hypertrophy; Insulin resistance; Lipidomics; Metabolic syndrome

Indexed keywords

CALCIUM CYCLING REGULATORY PROTEIN; FATTY ACID; LYSOPHOSPHATIDYLCHOLINE; MEMBRANE PROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2; TROPONIN I; UNCLASSIFIED DRUG; FRUCTOSE;

ADRENERGIC SIGNALING RELATED CARDIAC HYPERTROPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CARDIOMYOPATHY; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIET; DISEASE SEVERITY; DOWN REGULATION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HIGH FRUCTOSE DIET; HYDROLYSIS; INSULIN RESISTANCE; LIPID DIET; LIPIDOMICS; LYSOPHOSPHATIDYLCHOLINE ASSOCIATED APOPTOTIC CARDIOMYOPATHY; MALE; MORPHOLOGY; MYOCARDIAL ADRENERGIC SIGNALING; NEWBORN; NONHUMAN; OBESITY; OVERNUTRITION; PATHOPHYSIOLOGY; PHENOTYPE; PRELOAD INDEPENDENT CONTRACTILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; ADVERSE EFFECTS; ANIMAL; APOPTOSIS; CARDIAC MUSCLE CELL; CARDIOMEGALY; CARDIOMYOPATHIES; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; APOPTOSIS; CARDIOMEGALY; CARDIOMYOPATHIES; CELL SURVIVAL; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; FRUCTOSE; INSULIN RESISTANCE; LYSOPHOSPHATIDYLCHOLINES; MALE; MYOCYTES, CARDIAC; OBESITY; RATS; RENIN-ANGIOTENSIN SYSTEM; TROPONIN I;

EID: 84964507430     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.03.239     Document Type: Article

References (49)

1. E. Standl, and O. Schnell A new look at the heart in diabetes mellitus: from ailing to failing Diabetologia 43 2000 1455 1469
2. S. Kenchaiah, J.C. Evans, D. Levy, P.W. Wilson, E.J. Benjamin, M.G. Larson, and et al. Obesity and the risk of heart failure N. Engl. J. Med. 347 2002 305 313
3. P. Iozzo, P. Chareonthaitawee, O. Rimoldi, D.J. Betteridge, P.G. Camici, and E. Ferrannini Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with type II diabetes Diabetologia 45 2002 1404 1409
4. K.G. Alberti, and P. Zimmet Global burden of disease - where does diabetes mellitus fit in Nat. Rev. Endocrinol. 9 2013 258 260
5. L. Guariguata By the numbers: new estimates from the IDF diabetes atlas update for 2012 Diabetes Res. Clin. Pract. 98 2012 524 525
6. M.E. Young, P. McNulty, and H. Taegtmeyer Adaptation and maladaptation of the heart in diabetes: part ii: potential mechanisms Circulation 105 2002 1861 1870
7. A.M. From, C.L. Leibson, F. Bursi, M.M. Redfield, S.A. Weston, S.J. Jacobsen, and et al. Diabetes in heart failure: prevalence and impact on outcome in the population Am. J. Med. 119 2006 591 599
8. G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, C.J. Paciorek, and et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 2011 31 40
9. G.M. Reaven Banting lecture 1988. Role of insulin resistance in human disease Diabetes 37 1988 1595 1607
10. A. Ilercil, R.B. Devereux, M.J. Roman, M. Paranicas, M.J. O'Grady, E.T. Lee, and et al. Associations of insulin levels with left ventricular structure and function in American Indians: the strong heart study Diabetes 51 2002 1543 1547
11. R.M. Witteles, and M.B. Fowler Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options J. Am. Coll. Cardiol. 51 2008 93 102
12. H. Ashrafian, M.P. Frenneaux, and L.H. Opie Metabolic mechanisms in heart failure Circulation 116 2007 434 448
13. A. Van den Bergh, W. Flameng, and P. Herijgers Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions Eur. J. Heart Fail. 8 2006 777 783
14. J. Buchanan, P.K. Mazumder, P. Hu, G. Chakrabarti, M.W. Roberts, U.J. Yun, and et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity Endocrinology 146 2005 5341 5349
15. Y.T. Zhou, P. Grayburn, A. Karim, M. Shimabukuro, M. Higa, D. Baetens, and et al. Lipotoxic heart disease in obese rats: implications for human obesity Proc. Natl. Acad. Sci. U. S. A. 97 2000 1784 1789
16. D.D. Belke, S. Betuing, M.J. Tuttle, C. Graveleau, M.E. Young, M. Pham, and et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression J. Clin. Invest. 109 2002 629 639
17. A.S. Leopoldo, M.M. Sugizaki, A.P. Lima-Leopoldo, A.F. do Nascimento, A. Luvizotto Rde, D.H. de Campos, and et al. Cardiac remodeling in a rat model of diet-induced obesity Can. J. Cardiol. 26 2010 423 429
18. R.H. Eckel, S.M. Grundy, and P.Z. Zimmet The metabolic syndrome Lancet 365 2005 1415 1428
19. J.P. Despres, I. Lemieux, J. Bergeron, P. Pibarot, P. Mathieu, E. Larose, and et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk Arterioscler. Thromb. Vasc. Biol. 28 2008 1039 1049
20. T. McLaughlin, G. Allison, F. Abbasi, C. Lamendola, and G. Reaven Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals Metabolism 53 2004 495 499
21. S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin, and et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Executive summary Cardiol. Rev. 13 2005 322 327
22. Z. Wang, L. Li, H. Zhao, S. Peng, and Z. Zuo Chronic high fat diet induces cardiac hypertrophy and fibrosis in mice Metabolism 64 2015 917 925
23. F. Dong, Q. Li, N. Sreejayan, J.M. Nunn, and J. Ren Metallothionein prevents high-fat diet induced cardiac contractile dysfunction: role of peroxisome proliferator activated receptor gamma coactivator 1alpha and mitochondrial biogenesis Diabetes 56 2007 2201 2212
24. A.A. Bouchard-Thomassin, D. Lachance, M.C. Drolet, J. Couet, and M. Arsenault A high-fructose diet worsens eccentric left ventricular hypertrophy in experimental volume overload Am. J. Physiol. Heart Circ. Physiol. 300 2011 H125 H134
25. K. Mellor, R.H. Ritchie, G. Meredith, O.L. Woodman, M.J. Morris, and L.M. Delbridge High-fructose diet elevates myocardial superoxide generation in mice in the absence of cardiac hypertrophy Nutrition 26 2010 842 848
26. E.D. Frantz, C. Crespo-Mascarenhas, A.R. Barreto-Vianna, M.B. Aguila, and C.A. Mandarin-de-Lacrda Renin-angiotensin system blockers protect pancreatic islets against diet-induced obesity and insulin resistance in mice PLoS One 8 7 2013 e67192 10.1371/journal.pone.0067192
27. M.J. Raher, H.B. Thibault, E.S. Buys, D. Kuruppu, N. Shimizu, and A.L. Brownell A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload Am. J. Physiol. Heart Circ. Physiol. 295 2008 H2495 H2502
28. L. Pulakat, V.G. DeMarco, S. Ardhanari, A. Chockalingam, R. Gul, and A. Whaley-Connell Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities Am J Physiol Regul Integr Comp Physiol. 301 2011 R885 R895
29. D.J. Autelitano, R. Ridings, and F. Tang Adrenomedullin is a regulated modulator of neonatal cardiomyocyte hypertrophy in vitro Cardiovasc. Res. 51 2001 255 264
30. J.Y. Deng, P.S. Hsieh, J.P. Huang, L.S. Lu, and L.M. Hung Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways Diabetes 57 2008 1814 1823
31. J.P. Huang, S.S. Huang, J.Y. Deng, C.C. Chang, Y.J. Day, and L.M. Hung Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin Free Radic. Biol. Med. 48 2010 1710 1721
32. C.F. Huang, M.L. Cheng, C.M. Fan, C.Y. Hong, and M.S. Shiao Nicotinuric acid: a potential marker of metabolic syndrome through a metabolomics-based approach Diabetes Care 36 2013 1729 1731
33. H.Y. Ho, M.L. Cheng, M.S. Shiao, and D.T. Chiu Characterization of global metabolic responses of glucose-6-phosphate dehydrogenase-deficient hepatoma cells to diamide-induced oxidative stress Free Radic. Biol. Med. 54 2013 71 84
34. K.H. Chen, M.L. Cheng, Y.H. Jing, D.T. Chiu, M.S. Shiao, and J.K. Chen Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats Am. J. Physiol. Endocrinol. Metab. 301 2011 E853 E863
35. S.C. Kolwicz, S. Jr Purohit, and R. Tian Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes Circ. Res. 113 2013 603 616
36. E.D. Abel, S.E. Litwin, and G. Sweeney Cardiac remodeling in obesity Physiol. Rev. 88 2008 389 419
37. D.J. Chess, and W.C. Stanley Role of diet and fuel overabundance in the development and progression of heart failure Cardiovasc. Res. 79 2008 269 278
38. G.W. Lambert, N.E. Straznicky, E.A. Lambert, J.B. Dixon, and M.P. Schlaich Sympathetic nervous activation in obesity and the metabolic syndrome - causes, consequences and therapeutic implications Pharmacol. Ther. 126 2010 159 172
39. C. Rask-Madsen, and C.R. Kahn Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease Arterioscler. Thromb. Vasc. Biol. 32 2012 2052 2059
40. E.D. Motley, S.M. Kabir, C.D. Gardner, K. Eguchi, G.D. Frank, T. Kuroki, and et al. Lysophosphatidylcholine inhibits insulin-induced Akt activation through protein kinase C-alpha in vascular smooth muscle cells Hypertension 39 2002 508 512
41. C.A. Sargent, O. Vesterqvist, M.L. Ogletree, and G.J. Grover Effects of endogenous and exogenous lysophosphatidylcholine in isolated perfused rat hearts J. Mol. Cell. Cardiol. 25 1993 905 913
42. P. Lin, and R.D. Ye The lysophospholipid receptor G2A activates a specific combination of G proteins and promotes apoptosis J. Biol. Chem. 278 2003 14379 14386
43. M. Takahashi, H. Okazaki, Y. Ogata, K. Takeuchi, U. Ikeda, and K. Shimada Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism Atherosclerosis 161 2002 387 394
44. H.M. Chen, J.H. Hsu, S.F. Liou, T.J. Chen, L.Y. Chen, C.C. Chiu, and et al. Baicalein, an active component of Scutellaria baicalensis Georgi, prevents lysophosphatidylcholine-induced cardiac injury by reducing reactive oxygen species production, calcium overload and apoptosis via MAPK pathways BMC Complement. Altern. Med. 14 2014 233 10.1186/1472-6882-14-233
45. 2 activity, inflammation markers, and LDL alterations in obesity with or without type 2 diabetes Obesity Vol. 18 2010 Silver Spring Md. 2023 2029
46. E.S. Leinonen, A. Hiukka, E. Hurt-Camejo, O. Wiklund, S.S. Sarna, L. Mattson Hulten, and et al. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes J. Intern. Med. 256 2004 119 127
47. 2: the cardiovascular risk in young finns study Arterioscler. Thromb. Vasc. Biol. 30 2010 1861 1866
48. V. Magrioti, and G. Kokotos Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases Expert Opin. Ther. Pat. 20 2010 1 18
49. R.S. Rosenson, C. Hislop, D. McConnell, M. Elliott, Y. Stasiv, N. Wang, and et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial Lancet 373 2009 649 658